Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05456100

Chinese American Cancer Survivors Writing Study

A Randomized Controlled Trial Testing Expressive Helping for Chinese American Cancer Survivors

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
108 (estimated)
Sponsor
New York University · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

The Chinese American Cancer Survivors Writing Study is a Randomized Controlled Trial (RCT) testing the feasibility and efficacy of the Expressive Helping (EH) intervention among Chinese American cancer survivors.

Detailed description

Chinese Americans are one of the fastest growing immigrant groups in the United States, but there is still a lack of culturally-sensitive and linguistically-appropriate resources and interventions for this group. To address this gap, the investigators will examine the efficacy and feasibility of Expressive Helping, a writing intervention designed to lead participants to write about their cancer experiences. Participants will be adult cancer survivors of Chinese descent. After screening and consent, eligible participants will be enrolled in a 1:1:1 randomized controlled trial. Assessments of psychological symptoms will occur at baseline (prior to randomization), 1-month post-intervention, 3-months post-intervention, and 6-months post-intervention.

Conditions

Interventions

TypeNameDescription
BEHAVIORALExpressive HelpingExpressive helping involves a combination of emotional disclosure and peer support writing completed over four weeks.
BEHAVIORALExpressive WritingExpressive writing involves emotional disclosure writing over four weeks.
BEHAVIORALFactual WritingFactual writing involves writing facts about cancer treatment and experiences over four weeks.

Timeline

Start date
2022-07-14
Primary completion
2026-06-30
Completion
2026-12-31
First posted
2022-07-13
Last updated
2025-12-09

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT05456100. Inclusion in this directory is not an endorsement.